Pharma BD Deal Intelligence
A $3B carve-out that made Biocon Biologics a top-tier global biosimilars player by absorbing Viatris's entire biosimilars portfolio in one stroke. The asset purchase gave Biocon instant scale and commercial infrastructure, positioning it among the largest biosimilar suppliers worldwide.
Biocon Biologics to acquire Viatris' global biosimilars assets for up to $3.335 billion in stock and cash, creating a unique fully vertically integrated global…
Biocon Biologics acquired Viatris biosimilars business for $3B.
Dec 6, 2025: Viatris agreed to monetize its convertible preferred equity stake in Biocon Biologics Limited, selling to Biocon Limited for total consideration…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Biocon Biologics acquired Viatris biosimilars business for $3B.
$45.0B Global Biosimilars Market (2024)
The global biosimilars market is rapidly expanding as originator biologics lose exclusivity. Biocon Biologics acquired Viatris entire biosimilar portfolio, creating a vertically integrated manufacturer and distributor spanning 120+ countries with 7+ biosimilar products.
Key products include biosimilars of trastuzumab, pegfilgrastim, bevacizumab, insulin glargine, insulin aspart, adalimumab, and etanercept. US adalimumab biosimilar launch is a significant commercial opportunity given Humiras ~$21B peak revenue.
Biocon Biologics Ltd. completed a asset purchase transaction with Viatris Biosimilars Business.
Biocon Biologics completed integration of the acquired Viatris global biosimilars business across major markets ahead of plan (emerging markets July 2023, North America Sept 2023, Europe Dec 2023), taking direct commercial and regulatory control of its biosimilar portfolio.
Viatris agreed to sell its convertible preferred equity stake in Biocon Biologics Limited to Biocon Limited for $815M ($400M cash + $415M newly issued Biocon shares), unwinding the equity portion of its 2022 consideration. Expected to close Q1 2026; accelerates expiry of biosimilars non-compete restrictions.
Significant transaction at $3,000M. Biocon Biologics acquired Viatris biosimilars business for $3B.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Biocon Biologics Ltd. / Viatris Biosimilars Business (this deal) | 2022 | $3.0B | 72 |
| Merck & Co. Inc. / Moderna, Inc. | 2022 | $250M | 86 |
| Takeda Pharmaceutical Company Ltd. / Nimbus Lakshmi | 2022 | $6.0B | 82 |
| Johnson & Johnson / Abiomed Inc. | 2022 | $16.6B | 74 |
| Amgen Inc. / Horizon Therapeutics plc | 2022 | $27.8B | 72 |
| GSK plc / Sierra Oncology Inc. | 2022 | $1.9B | 70 |
| Bristol-Myers Squibb Company / Turning Point Therapeutics Inc. | 2022 | $4.1B | 70 |
← Browse all deals · How we score deals
More: 2022 deals